Adamas Pharmaceuticals Inc (NASDAQ:ADMS) was the target of unusually large options trading on Tuesday. Traders acquired 1,604 call options on the stock. This is an increase of approximately 1,504% compared to the average daily volume of 100 call options.

Adamas Pharmaceuticals (NASDAQ ADMS) opened at $35.61 on Friday. The company has a market cap of $811.16, a P/E ratio of -10.60 and a beta of 1.13. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals has a fifty-two week low of $13.50 and a fifty-two week high of $38.22.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.03). The company’s revenue was down 99.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.66) EPS. research analysts predict that Adamas Pharmaceuticals will post -3.84 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Adamas Pharmaceuticals in the third quarter valued at $110,000. Quantbot Technologies LP acquired a new position in shares of Adamas Pharmaceuticals during the third quarter valued at about $119,000. Tower Research Capital LLC TRC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at about $109,000. Sei Investments Co. raised its holdings in shares of Adamas Pharmaceuticals by 1,105.0% during the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after purchasing an additional 8,033 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at about $184,000. Institutional investors own 79.40% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Adamas Pharmaceuticals in a research note on Sunday, September 17th. Mizuho reissued a “buy” rating and issued a $48.00 target price (up from $26.00) on shares of Adamas Pharmaceuticals in a report on Tuesday, September 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Finally, Noble Financial restated a “buy” rating and issued a $33.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, September 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Adamas Pharmaceuticals has an average rating of “Buy” and an average target price of $44.86.

TRADEMARK VIOLATION NOTICE: “Stock Traders Purchase High Volume of Call Options on Adamas Pharmaceuticals (ADMS)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/stock-traders-purchase-high-volume-of-call-options-on-adamas-pharmaceuticals-adms/1803711.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.